TALK© is a communication tool which aims to guide multi-professional clinical teams learning and improving quality of patient care and patient safety together. It is a simple and practical approach to multi-professional structured feedback and debriefing, to be used after unplanned learning events in clinical environments. Debriefing is the process of an individual or team formally reflecting on their performance after a particular task, a shift or a critical event (World Health Organisation 2009). TALK proposes an easy way to guide a constructive conversation between team members whenever new insights might be learnt from clinical experience. This includes cases or sessions in which things went well but also near misses and untoward events. Patient safety is far too often threatened by unidentified system flaws, poor practices, weaknesses in team communication and lack of appropriate action after critical events. The relevance of a culture of safety and communication is emphasized by WHO advocating debriefing in its Human Factors review, 2009. This RISE project will consist of three phases; firstly secondees will contribute to parallel implementation processes in specified units across the 3 participating countries and will undertake research to better understand the benefits of structured debriefing, communication and organisational culture. Secondly, using the data generated from the research study, further training materials will be developed and translated to support the wider deployment of the TALK tool. Thirdly, the TALK tool will be widely disseminated as a structured debriefing tool and implemented across and beyond all participating partners and its impact will be assessed.

Parkinson Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. There is an unmet clinical need to treat Parkinson disease with mild cognitive impairment (PD-MCI). There is ample evidence from epidemiological studies as well as (pre)clinical research that Nicotinic receptors are involved in PD and cognition. Recently a clinical trial suggested that selective α7 nicotinic receptor agonist improved cognition in PD patients, as a secondary outcome measure. Hence, the main goal of PD-MIND is to show the potential of the Astrazeneca nicotinic α7 agonist AZD0328 in a randomized, placebo-controlled, international multicentre, cross-over study on cognition in people diagnosed with PD-MCI. We will assess the Attention Intensity Index composite score from the CogTrackTM system as primary outcome measure and other clinical aspects (cognition, motor symptoms) as secondary outcomes. In addition, blood, CSF and imaging biomarkers will be assessed as potential predictors of response, and as marker of target involvement. Patients (Public and Patient Involvement) and other stakeholders will be engaged from the start to allow integration of end-user perspectives in the design and execution of the project. PD-MIND will put considerably effort to disseminate and exploit clinical outcome data and biomarker results, and to sustain the partnership for subsequent phase 3 clinical studies. PD-MIND consortium consist of world-leading PD-MCI experts in the area of clinical trials, clinical coordination, project management, data management and analysis, and biomarkers. As such the consortium is well positioned to execute the proposed work and complement the EFPIA members.

The ultimate purpose of ANYWHERE is to empower exposed responder institutions and citizens to enhance their anticipation and pro-active capacity of response to face extreme and high-impact weather and climate events. This will be achieved through the operational implementation of cutting-edge innovative technology as the best way to enhance citizen's protection and saving lives. ANYWHERE proposes to implement a Pan-European multi-hazard platform providing a better identification of the expected weather-induced impacts and their location in time and space before they occur. This platform will support a faster analysis and anticipation of risks prior the event occurrence, an improved coordination of emergency reactions in the field and help to raise the self-preparedness of the population at risk. This significant step-ahead in the improvement of the pro-active capacity to provide adequate emergency responses is achievable capitalizing on the advanced forecasting methodologies and impact models made available by previous RTD projects, maximizing the uptake of their innovative potential not fully exploited up to now. The consortium is build upon a strong group of Coordinators of previous key EC projects in the related fields, together with 12 operational authorities and first responders institutions and 6 leading enterprises of the sector. The platform will be adapted to provide early warning products and locally customizable decision support services proactively targeted to the needs and requirements of the regional and local authorities, as well as public and private operators of critical infrastructures and networks. It will be implemented and demonstrated in 4 selected pilot sites to validate the prototype that will be transferred to the real operation. The market uptake will be ensured by the cooperation with a SME and Industry Collaborative Network, covering a wide range of sectors and stakeholders in Europe, and ultimately worldwide.